诱导多能干细胞与心血管精准医学  

Induced pluripotent stem cells and cardiovascular precision medicine

作　　者：叶领群 倪萱 韩兴龙[1] 赵振奥[1] 雷伟[1] 胡士军[1] YE Lingqun;NI Xuan;HAN Xinglong;ZHAO Zhen’ao;LEI Wei;HU Shijun(Department of Cardiovascular Surgery of the First Affiliated Hospital,Institute for Cardiovascular Science,State Key Laboratory of Radiation Medicine and Protection,Medical College,Soochow University,Suzhou 215000,China)

机构地区：[1]苏州大学附属第一医院心脏大血管外科,苏州大学心血管病研究所,放射医学与辐射防护国家重点实验室,苏州大学医学部,苏州215000

出　　处：《生命的化学》2020年第5期643-653,共11页Chemistry of Life

基　　金：国家重点研发计划项目(2017YFA0103700);国家自然科学基金项目(91949111,81770257);航天医学基础与应用国家重点实验室开放基金资助项目(SMFA17K02)。

摘　　要：近年来,心血管疾病已经成为人类健康的最大威胁。然而,由于缺乏能够真实地模拟患者生理病理状态的疾病模型,心血管疾病的发生发展过程中许多重要的分子途径仍然未显现出临床转化前景。随着诱导多能干细胞技术的出现,体外可以建立具有特异遗传背景和表观遗传调控的疾病模型,这为心血管疾病精准医学提供了一个独特的平台。该文将重点介绍诱导多能干细胞技术在各种心血管疾病模型、药物评估及筛选方面的应用。In recent years,cardiovascular disease has become the greatest health threat to humans.However,due to the lack of disease models that can realistically simulate the physiological and pathological state of the patients,many of the molecular pathways that are thought to be essential in the development of cardiovascular disease processes still have unknown clinical significance.With the emergence of induced pluripotent stem cells,a unique platform for cardiovascular disease has been established to set up a disease model with specific genetic background and epigenetic regulation from the cellular level in vitro.In this review,we described the translational applications of iPSCs in cardiovascular precision medicine,such as disease modeling,drug screening and so on.

关 键 词：诱导多能干细胞 心血管疾病 精准医学 疾病模型 药物筛选 

分 类 号：R54[医药卫生—心血管疾病]